The clinical syndrome of heart failure (HF) can be described as the reduced capacity of the
heart to deliver blood throughout the body. To compensate for inadequate tissue perfusion …

Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) that has
been recommended in clinical practice guidelines to reduce morbidity and mortality in …

Despite significant advances in the last 30 years in reducing morbidity and mortality from
heart failure with reduced ejection fraction (HFrEF) with pharmacological and device-based …

Heart failure (HF) treatment has changed substantially over the last 30 years, leading to
significant reductions in mortality and hospital admissions in patients with HF with reduced …

Heart failure (HF) impacts an estimated 5.7 million Americans, and its prevalence is
projected to increase to more than 8 million Americans in the next 15 years. Key clinical …

Purpose of review Compared to enalapril, use of angiotensin-receptor blocker and
neprilysin inhibitor sacubitril/valsartan to treat patients with heart failure and reduced …

Objectives: The aim of this study was to assess the prevalence and variation in angiotensin
receptor/neprilysin inhibitor (ARNI) prescription among a real-world population with heart …

Introduction The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan
(SAC/VAL) has shown benefit in patients with symptomatic heart failure (HF), including those …

Objective To investigate whether hypotensive patients diagnosed with heart failure and
reduced ejection fraction (HFrEF) might benefit from angiotensin receptor–neprilysin …

Abstract Aims Sacubitril/Valsartan (Sac/Val) was proven more effective than enalapril for
symptomatic patients with heart failure (HF) with reduced ejection fraction (HFrEF). This …